Rocket Pharmaceuticals Q2 2026 earnings: PRV sale drives $123 million net income

Rocket Pharmaceuticals (NASDAQ: RCKT) reported Q2 2026 net income of $123.2 million, compared with a $68.9 million net loss a year earlier, while diluted EPS was $1.08 versus a loss per share of $0.62. The turnaround was driven primarily by a $178.2 million gain from selling a Priority Review Voucher rather than operating profitability. Lower research and administrative spending also narrowed the operating loss, while quarter-end cash and investments reached $283.7 million.

Core Financial Results

The quarterly financial statement did not report revenue, and KRESLADI commercial availability is not planned until Q4 2026. Operating expenses declined as Rocket reduced R&D and G&A spending, while the prior-year period also included a $3.5 million restructuring charge that did not recur.

The largest financial change came below the operating line: the Priority Review Voucher sale generated $180 million in gross proceeds and a $178.2 million net gain.

R&D spending fell primarily because of lower manufacturing, development and direct material costs, reduced headcount-related compensation, lower depreciation and lower clinical trial expenses. G&A decreased mainly due to reduced commercial preparation spending and headcount, as well as lower legal expenses.

The PRV Sale, Not Operations, Produced the Quarterly Profit

Rocket still recorded a $46.9 million operating loss in Q2. The $178.2 million net gain from monetizing the Rare Pediatric Disease Priority Review Voucher lifted pretax income to $131.8 million; after an $8.6 million income-tax provision, net income was $123.2 million.

This distinction is important because the voucher sale is a one-time capital event rather than recurring product revenue. At the same time, the reduction in operating expenses shows that Rocket’s more focused cost structure is lowering its underlying quarterly loss.

Cash, cash equivalents and investments totaled $283.7 million at June 30, 2026, up from $188.9 million at December 31, 2025. The company attributed the stronger cash position to the PRV proceeds, which provide non-dilutive funding for its prioritized cardiovascular pipeline.

Pipeline and Commercial Progress

RP-A501 in Danon disease

All three initial patients treated under the modified pivotal Phase 2 protocol completed the required safety observation period. Rocket reported no thrombotic microangiopathy, capillary leak syndrome or other significant safety concerns at the recalibrated dose of 3.8 × 10¹³ GC/kg with the refined immunomodulatory regimen.

Rocket is engaging with the FDA to determine the path for dosing additional patients and completing the pivotal trial. A regulatory-pathway update and a broader Danon disease program update are expected in the second half of 2026. The related natural-history study has enrolled more than 50 patients.

KRESLADI commercialization

KRESLADI received FDA accelerated approval for severe leukocyte adhesion deficiency-I, becoming Rocket’s first approved product. The company is building a focused commercial model around a limited network of specialized treatment centers and expects commercial availability and patient onboarding to begin in Q4 2026.

Because the approval is accelerated, continued approval may depend on verification and description of clinical benefit through follow-up and additional post-marketing data. The prescribing information also identifies risks including serious infections, veno-occlusive disease, engraftment complications and potential lentiviral vector-mediated insertional oncogenesis.

Other cardiovascular programs

Rocket continues discussions with the FDA about the design of a potential pivotal study for RP-A601 in PKP2 arrhythmogenic cardiomyopathy. A regulatory update is expected in the second half of 2026, while the Phase 1 study remains open and enrolling.

For RP-A701 in BAG3-associated dilated cardiomyopathy, patient screening and enrollment have started. Initial dosing in the Phase 1 study is anticipated in the second half of 2026.

Cash Runway Guidance

Based on its current operating plan, Rocket expects its June 30 liquidity to fund operations into Q2 2028. The company did not provide a prior runway estimate in the supplied results for comparison.

The runway gives Rocket additional time to pursue its planned clinical and regulatory milestones, although the estimate remains dependent on the current operating plan.

Recent Insider Transactions

The supplied insider record shows both market transactions and an option or derivative exercise. These transactions are presented objectively and do not, by themselves, establish insiders’ views of Rocket’s prospects.

Risks Investors Need to Watch

• Profit was driven by a nonrecurring transaction. Rocket remained loss-making at the operating level, so future profitability cannot be inferred from Q2 net income or EPS.
• RP-A501 still requires regulatory alignment and additional clinical execution. The initial safety update covered only three patients, and the FDA pathway for dosing more patients and completing the pivotal study remains under discussion.
• KRESLADI faces launch and post-approval requirements. Commercial availability is planned for Q4 2026, but the target population is ultra-rare and continued approval may depend on verification of clinical benefit.
• The cash runway is plan-dependent. The estimate into Q2 2028 assumes Rocket follows its current operating plan while continuing to fund multiple clinical and commercial programs.

Summary

Rocket’s Q2 2026 results materially improved its financial position through the PRV sale and a lower operating cost base, but the reported profit was not generated by recurring operations. The next major indicators will be FDA alignment on RP-A501 and RP-A601, initial RP-A701 dosing, and the start of KRESLADI patient onboarding in Q4 2026.